IN THE Press

2024

December 13, 2024

Next Gen Diagnostics Developing Automated NGS Workflow for Outbreak Detection, Antibiotic Resistance Dx

Next Gen Diagnostics (NGD) is eyeing the clinical microbial genomics market with ahighly automated, end-to-end next-generation sequencing and analysis workflow.

The Boston-based company is planning to deploy its technology into hospitals for NGS-basedinfectious disease control in early 2025, and is developing a sequencing-based diagnostic test todetermine microbes' antibiotic susceptibility and resistance.

NGD Founder and CEO Paul Rhodes said the company was established in 2017 with the goal ofachieving high-volume and low-cost whole-genome sequencing for routine clinical microbiologyapplications. Although the cost of sequencing has been going down in recent years, Rhodes said thecompany has been working to address two other major bottlenecks that hinder the wide adoption ofNGS in the field: sample preparation and bioinformatic analysis.